COCRYSTAL PHARMA, INC. Accounts Receivable, Fair Value Disclosure
COCRYSTAL PHARMA, INC. (COCP) had Accounts Receivable, Fair Value Disclosure of $400.00 thousand as of 2013-09-30, per its 10-Q filed 2013-11-18.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Financial Instruments, Financial Assets, Balance Sheet Groupings
us-gaap:AccountsReceivableFairValueDisclosure · last filed 2013-11-18
- 2013-09-30: Accounts Receivable, Fair Value Disclosure $400.00K.
| Period end | Accounts Receivable, Fair Value Disclosure |
|---|---|
| 2013-09-30 | $400.00K 10-Q · filed 2013-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |